Provided are compositions comprising sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)], and uses of these in the treatment of cancer. The compositions involve the delivery of 400-1562.5 mg or 320-625 mg/m2 of the compound based on the body surface area of the patient, and contain a reduced amount of indazolium hydrochloride. The dosage range is based on the minimum effective dose and maximal tolerated dose of the compound. Further provided is the use of the compound in the treatment of cancer by particular administration schedules, and with the administration of a drug to prevent infusional fever which can be a side effect of intravenous sodium trans-[tetrachlorobis(1H-indazole)ruthenate (III)] administration.
